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Because cardiac ontractility is depressed in patients with 
chronic heart fake, the use of positive inotropic agents has 
been regarded as a logical approach to the treatment ofthis 
disorder. The delivery of calcium ions to myoEbrillar ele- 
ments is impaired inthe failiug heart; the resultant decline in 
the number oftensi~u-generating sitesleads to a reduction i
the maximal IMe that can be achieved during systole (l-4). 
This depression ofwntmctility has loq~ been considered to
be the primary defect in patients with heart failure, aud belief 
in this principle has led to the development of positive 
&tropic agents that can increase the delivery of calcium to 
the myo6laments byincreasing the intracellular concentra- 
tion of calcium in the failin heart. 
During the last 200 years, numerous agents with positive 
inotropic activity have been developed and evahmted for the 
treatment ofheart faihue. In general, these drugs have had 
mauy ofthe characteristics of an ideal pharma&ogic agent 
for the management of his disorder. AU positive inotropic 
agents augment cardiac performance and improve blood flow 
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to peripheral organs. Most of these drugs also act directly or 
inditectly to dilate peripheral b ood vessels and thus reduce 
ventricular wall stress and myocardii oxygen consumptiou. 
In addition, many positive inotropic agents exert favorable 
effects on ventricular relaxation, coronary blood flow and 
the activation of neurohormonal systems. The possibility 
that many of the physiologic abnormalities in heart failure 
can be ameliorated bythe admiuistratiou f a sh@e phar- 
macologic agent has stimulated considerable interest inthis 
class of drugs. 
Despite the many theorek reasons why pusitive inobup- 
ic agents hould be useM in patients with chronic heart 
faihue, these drugs have not yet achieved an estabhshed 
phzeinthe~ofthisdisorder.Despitefavorable 
andoftendramatichemodynamiceEects,theinttoductionof 
each positive inotropic agent into clinical medicme has 
engendered great discussion and debate ver since the 
introduction fdiitalis into clinical medicine more than ZKI 
years ago. Physicians have raised questions about he elb 
cacy of each candidate, and these doubt.~ have been pd- 
leled by concerns about he safety of each drug. This pattern 
seemstobeuniquetothedevelopmentofpositive~ 
drugs; similar controversies have not generally accompanied 
the use of diuretic drugs, vasodilators or converting myme 
inhibitors. 
Why has it been so dithcult to develop ositive bmt@c 
ageptsforthetreatmentofchronicheartfailure~~psrt,~e 
&hate over these agents rages because physiciws have not 
dVCdtheiBBUC~tOWhetherthefRiUU#heertBhdbe 
plmndo@caUystimulrrted.Ifthe~ofa~ 
tiiityinheartfaibueisacompensatoryresponseintendedto 
raduce energy cotummption (5), then the failing heart should 
berestedratherthen~~,thus,itmaybeimpoeslweto 
developasafeand&tivepoBitive&tropicdrugfmthe 
ueatmentofheartikihue.However,ifthedepressiond 
cardiaccontr&ityisafitndamentaldekiencyinheart 
failurethatneedstobeaddressed,thenstimuMmofthe 
hesrtisah$hlydeshablegoal,andweBhotddtryto 
undetMandwherewehavegweastrayiniiMingthetrue 
potentialofthistherapeuticacea 
In this review we will attempt to elucidate why the 
developlnentOfwtiWinotropicdrugBfrwheartfaiiure 
has been M) Mknging. To do so, we will unuider the 
experknce with three ciasses of positive inotropic agents: 
1) digitalis glycosks, 2) cyclic *nosine monophosphate 
(AkPMhancing drugs (beta-agonists andphosphodiester- 
ase inhibitors), and 3) vasodilator drugB with dii positive 
inouopk actions (hydrkhte and iiosequinan). 
Digitalis W the first paarmacologic a ent with positive 
inotropicactionsthatgainedwidespreaduseintheueatmem 
ofchumicheartibiiure. Fo many yearsafteritsintroduction 
~f$&aImedicine,d@alkwasbelievedtoactasa 
diureticdntg,pethapsbecauseatthatthne,heartiMuewas 
primarily e as an edematous state. In the 19OOs, when 
heartikilure was recognized to be a hemodynamic disorder, 
digitalis was discovered to have positive inotropic effects 
(6.7). The dtuq augments cardii conttactility b  inhibiting 
the activity of sodium-potassium adenosine triphosphatase 
(8); the resulting iucrea~e in the concentration ofhtuacellu- 
larsodiume&ancestheentryofcalciumintoceUsby 
increasi~ calcium-sodium exchange. However, digitalis 
notBimplyapositive&tropicagent.Thedru9alBorestores 
theinhibitorye&ctofcaniiac -oUQ-hetic 
outflow from the central nervous system and thus reduces 
the activation f both the sympathetic nervous system and 
the renin~nsin system (9.10). This additional action of 
dighahs as teceived considerable attention in recent years, 
nowthatheartfaiIureisbeingrega&dbymanyinvestiga- 
tom a~ a neurohonnonal disorder (1 I). 
On the baBis of these favomble pharmacologic properties, 
wewouldexpectdieitalistobeahighlyeffectivedrugforthe 
treatment of heart failure. However, iixuu the time of its 
introduction by withering and for most of the 26th century, 
physicianBhaveat9uedabouttheeUicacyandBefetyofthe 
dnUr(l2).Manysugeestedthatthe~wasnotuseNinthe 
treatment of heart failure in patients in normal sinus rhythm 
(13).othersbeliewdtbattheedventofpotentdiureticdrugs 
inthe1%USlMdedigi~UMeCeSSarybecauseIUOSt~- 
tientswithheartfaihuecouldbewithdrawnfiomueatment 
with the chug without adverse wnseqwnces (14,15). In
dditiw, many phy3i~ians raised concerns about the safety 
ofdi&alisinthetreatmentofheartihhre.ThedNg 
commonly caud glstrointeBtinal distress, ventricular r- 
rhythmias nd heart block, aud these side effects were 
fmquemly serious enough to krease the morbidity and 
mormhty of treated patients (16). Twenty percent to30% of 
*nts teceiving digitat in the 1960s and 1970s expek 
ea~seTioustoxicityframthe~,andnearly2096to~ 
of these patknts with diis toxicity died (16-19). Given 
uncer&ties about the e&acy of digitalis and con- 
cenu about i s safety, many physicians recomme ndedthatit 
be abandoned for the treatment of heart failure. 
What could explain the poor long-term cliial results 
with a drug that exerted such favorable pharmacologic 
e&cts? Many physicians were not surprhed by the clinical 
results with digitalis because they believed that all positive 
inotropic agents, by enhancii q yocawhal oxygen con~ump 
tion and ventricular arrhythmias, would increase cardiovaB- 
c&r morbidity and mortality. Other physicians s-ted 
that di@alii failed not because ofhow the drug acted, but 
because of how it wan used. Ever since its introduction by 
Withering physicians were taught to administer digitalis 
rapidly in inctemental doses until either the patient’s condi- 
tion improved (adiutesis began) or the patient developed 
serious side ffectB (toxicity became evident). This approach 
wan embodied in the concept of“digitaliiation”; that is, to 
produce a therapeutic e&c& it was necessary toachieve 
high levels of di&alii rapidly. Was it possible that he doBes 
of digit lis were increased soquickly that au e&&e dose 
of the drug was missed? The concept that low doses of 
diitalis might be as effective as(but better tolerated than) 
high doses was recently tested in several wntrolled clinical 
trials. These studies (XL24) demonstrated con~htently that 
low doses of digoxin lessened the symptoms and increased 
the exercise tolerance ofpatients with chronic heart fail- 
-without evidence ofserious toxicity. 
What can we learn about the development of positive 
inotmpic agents fionr the experience with digital? At first 
glance, these observaGonB sugqeBt that it might be possible 
to develop uBeiX poBitive htotropic agents for the treatment 
of heart fake if low doses of these drugs were used. Yet, 
such a conclusion would be warranted only if we knew that 
theselowdoseswere&icaUye&tivebecatuedtheir 
ability toincreaBe catdiac conuactility. Although we recog- 
nixethatlargedosesofdi@alisexertpositiveiuotropic 
actions (6,7), it is not clear that low doses of the drug 
stimulate the heart. Instead, low doses of di#alis may act 
primarily on the autonomic nervous system to correct the 
nemohormonal abmmuahties of patients with heart failure 
(23). Thes  neurohormonal e&ts could explain mauy (iinot 
most)ofthehemodynamicandchnicalbenefttsofthedrugin 
the absence of any change inthe wntractile state of the heart 
(1125). This obsenxuion raises au int&uing possibility: 
Was digitalis nearly abandoned forthe tr&ment of heart 
Uueb causethedngwasdevelopedatdosesthatexert 
positive inouopic eikts? 
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Cyclic Adenosine Monophosphate-Enhancing 
Rsitive Inotropic Apts 
These positive inotropic agents augment cardii contrac- 
tility by increasing the concentration f intracellular cyclic 
AMP in the failii heart, which in turn enhances the entry of 
cakium into cells by activating membrane-bound calcium 
channels. Two types of cyclic AMP-enhancing drugs have 
been developed: beta-adrenergic re eptot agonists (which 
promote the synthesis of cyclic AMP) and phosphodiester- 
ase inhibitors (which inhibit he degradation f cyclic AMP). 
The development ofcyclic AMP-enhancing agents has been 
viewed as a particularly rational approach tothe treatment of 
chronic heart failure because cyclic AMP is deficient in 
Ming human hearts, especially those of patients in the 
tern&al stages of the disease (26). Furthermore, these drugs 
increase cardiac ontractility by utilizing an inotropic mech- 
anism that is identical to that normally utilixed to stimulate 
the heart during periods of stress. Finally, these drugs are 
not simply positive inotropic agents. They also exert favor- 
able e&cts on the periphetul blood vessels, the coronary 
circulation and ventrkular elaxation (27-29). For all of 
these reasons, most physicians expected cyclic AMP- 
enhancing drugs to be an etkctive and safe approach to the 
management of heart failure. 
Beta&wuxgie uuqtur agmdsts. Many orally active 
catecholamines have been developed for the treatment of
heart failure, includii be&agonists (for example, prenal- 
terol) and bet+agonists (for example, pirbuterol, salbuta- 
mol and terbutaline). Short-term therapy with these drugs 
produced notable increases incardii output and decreases 
in left ventricular llllii pressure (30-33). However, in most 
patients, the magnitude of the hemodynamic improvement 
seen atter the administtation f these drugs was modest and 
could not be sustained during long-term therapy (34). This 
atkwated hemodynamic response was related to a r&c- 
~inthedeasityof~~forthese~inthefailing 
heart, and the density of these receptors declined further 
during long-term treatment (34,35). These biochemical 
events explained why patients commonly developed toler- 
ance to the initial hemodynamic effects of the beta-receptor 
agonists (35). Consequently, these drugs were not shown to 
be clinically effective in doubleblind placebo-controlled 
trials (36-38). 
The observation that beta-adrenergic agonists produced 
only modest hemodynamic responses proved to be a great 
disappointment forthe clinical investigators involved in the 
development of these drugs because they considered a
pharmaw@ic mt to have great promise for the treatmeat 
of heart failure only ifit ptoduced substantial hemodynamic 
bene6ts.Asaresult,thteeapproa&esweteutilkedinan 
attempt to augment the hemodynamic response to these 
drugs. 1) Physicians increased the dose of the beta-agonists 
in an attempt to achieve greater hemodynamic benelk 
However, the use of such hi doses led to signiicant 
and gastrointestinal distress) (36). 2) ~hysi&ns adminis_ 
tered high doses of these drugs intermittently in an attempt 
to overcome the development of olerance, and prelii 
studies (3940) indicated that this intermittent approach 
might result in longterm hemodynamic and cliical bet&s. 
However, arandomized trial (41) of intermittent imhf~~ 
dobutamine was halted prematurely by the man&cutter 
when 15 of the 20 deaths in the study were seen in patients 
who were assigned or crossed over to tEatmemwithdobu- 
take. 3) Physicians attempted to reduce the side ekts of 
beta-agonists anti prevent the development of tolerance to 
thesedrugsbytheuseofapartialbeta-agonistsuchas 
xamoterol(42). and prehminary trials (43,44) SW that 
xamoterol could produce long-term hemodynamic and clin- 
icai benefits in patients with heart failure. However, the 
results of a large scale placeb~ntrolled trial (45) indicated 
that xamotetol increased the mortality of patients with 
severe heart failure. 
This combined experience indicated that attempts to 
utilize beta&nergic agonists to improve the hemody- 
namic status of patients with chronic heart faihue produced 
little clinical improvement and increased the risk of death. 
However, the development of he bemqonists was primar- 
ily guided by a single principle-that these drugs hould be 
administered to pro&e significant positive &tropic ef- 
fm. Hence, high doses were selected to product maximal 
enhancement of the systolic tktion of the left ventricle. 
Would the results of clinical studies have been diKetent if
lower doses of these m had been use&perhaps with the 
principal goal of imv.-iq diastolic function? m 
observations using such an approach were encouraging 
(43,44). However, because orally active beta-agonists areno 
longer being developed for the treatment of heart failure, this 
therapeutic possibility has been abandoned. 
inhtbk& Phosphodiesterase inhibi- 
tors increase intracellular levels of cyclic AMP in the failing 
heart by inhibiting the degnukion of the nucMide. In 
doing so, these drugs circumvent changes in the beta- 
adlene@c pathway that were responsible for reduciq the 
eiftcacy of the beta-adrenergic agonists. Many orally active 
ph~phodiesterase inhii have been developed fm the 
treatment of heart Shtre, in&ding amrinone, milrinone, 
enoximone, imaxodan, pimobendan d vesnarinoae. Short- 
term therapy with these drugs produced notable increases in
cardiac output and decreases in let? ventricular fill@ pns- 
sure (46-49). However, in many patients. the w of 
the hemodynamic bet&t was modest and thus the doses of 
these drugs were increased in an e&t to achieve maximal 
hetnodynatnic bet&s. With some drugs (for example. am- 
rinone), the attempt to use high doses led to significant 
adverse reactions (fm example, gasttointestiraal distress) 
(so,sl), so that patients generagy tokrated oses that pro- 
duced only small hemodynamic etkcts (52). However, for 
most agents in this class, higher doses prodd greater 
hemodynamiceUkctsand.incontrasttotindings~~ 
beta-agonists, these &cts were sustained during long-term 
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therapp without the development of pharmanolosic t&r- 
ante (48,53). 
~thouqhhighdosesofphosphodiesteraseiuhibitorspro_ 
duced marhed hemudynamic benefits, ~term therapy 
with these drugs did not produce onsistent chniad beneftts. 
An&me, mihkme, enoximone and imazodan tiled to 
decrease ymptoms or improve xetcise tolerance in con= 
t&led &ical trials (54-57). Instead, these studies raised 
coucernsthattheseaSentscould~~cubu 
arrhythmias, provohe myocardial ischemia, accekrate pro- 
~ouoftheuuderlyingdiseaseaudincreasemortality 
(58,59). Two small phu=bo.condlsd trials (3637) reported 
thattmatmemwithenoximoneandimazodaawasassociated 
with a sign&ant increase inmortahty. This rish was con- 
6rmed by the results of the Prospective Randomized Mihi- 
nmte survival Evaluation (I’ROMISE) trial (60), which dem- 
onstratedthatlon@rmtmatmem with milrkme increased 
themortabtyafpatkntswithseverecbrouicheartEailureby 
23%. The d&s adverse e&t on survival was particularly 
marlted in patients with class IV symptoms, who showed a 
53% increase inmortality. 
Giventhedrauu&hemodynamicimprovementproduced 
by the phospm inhibitors, what could explain the 
poor lou&term cliuical results with these drugs? Because 
cyclic AMP is toxic to myoca&al cells (61,62), some phy- 
siciaushavesugpsMthatloug-temttherapywithaphos- 
phodiesterase iuhibhorcould accelerate the mte of disease 
pmgeusk Others have suqgeskd that because high levels 
of iutracelhdar cyclic AMP act to enhauce automaticity, 
akrdepokixatums aud triqgered responses (63,64), these 
dtuqs could exacerbate ventricular tachyarrhythmias (58).
This hypothesis was upported by the findings of the PRCM- 
ISB study (6!!,66), in whiih mihinone iucreased not only the 
frequency and complexity of ventricular rhythmias, but 
also the rish of sudden death. This findinq raises the possi- 
bility that @xphodiesterase inbii could evolve as au 
e&ctiveaudsak&atmentforpatientswithchronicheart 
faihuw if their favorable hemodyuamic effects were pre- 
servedbuttheir&erseelecttuphysioloqiceBctswere 
minhnkd. This hypobis is supported bystudies showiug 
thatmihkoneprohmgslifewhenusedinanexperimental 
modelofheartfailumintberat(67),amudelhtwhichthe 
dnqtexertseiktsonlyonpeuipheralbloudvcsselsandnot 
ou the heart (68). 
Could the favorable and adverse e&cts of@osphodies- 
tereseMibiUrsbediiMciatedintheclhkalsettiug?Asin 
thecaseofthebeta&renerqicago&ts,thedevelopmentd 
phu@odiestemse hthibitors has been guided by a single 
~:‘ksedrugsshouldbeadministeredtoproduce 
sie~~antpositivehmtropiceikcts. Hence,hi&doseswen 
~~~produamaximalenhancemeatofthesystolic 
fbcth of the left ventricle. Would the results of clinical 
studiishavebeendikrentiflowerdosesofthe~dnlgs~ 
~~,~swiththeprh~cipalgoalofdikingperipb 
eralblood~ssdsratherthauincm~the~~ 
d~eheart?Supportforthishypothe&hasrecentlycome 
Born coutrolkd clinical trials usiug low doses ofeuoximoue 
and phuobeudan. In these studies (69.70). despite more 
m dest hemodynamic etkts, low doses of these drugs 
produced more cork&tent e&cts on symptoms aud exercise 
tolerance tbau did hii doses. 
Are such low doses of phosphodiesterase iuhibitors free 
of adverse etkts 011 mortality? This possiiity has beeu 
raised by the results of recent studii with vesuakme 
(OFc-8212). vtsnarirnone ex rtspositiveinott@cetfectsby 
hthiibitinq phosphodiesterase (in a manner similar to mihi- 
uone), but it also increases iutracelhdar levels of sodium, 
possiily by au agonist action on the sodium channel (71). 
Thi  a&m provides the dtug with many of the phsrmaco- 
logic haracteristics of a class III antiatrhythmic drug. The 
relative importauce ofthese two pharmacohgic actions may 
depend on the admink& dose of vesnarhume. Whereas 
high doses of the drug (120 to 240 mg as a single dose) 
produce favorable h-c e&cts in patkuts with 
heart failure by increasing myocardial contractility (72), low 
doses exert little hemodyuamic effect aud may have only an 
autiarrhytbmic action (73,74). These Gudhtgs suggest that 
low osesofve!makme ex rtanektoulyonthesodiim 
chanuel and that phosphodiesterase inhibition occurs only 
with high doses of the drug. This hypothesis is upported by 
the results of coutrolled clinical trials. Hiqh doses ofvesuari- 
none+uSicient to increase caulk contractihtyAtt~reased 
morMityhtpatientswithchronicheartfailure(75),whereas 
mortality was actually reduced by the admhdstratiou of low 
doses of the drug (75.76) that exert no hemodynamic e&t. 
These results support the concept that he adverse eikcts of 
positive~~tsousurvivalmaybe&tedtothe 
use of hemodynamicaily ektive doses of these drugs. 
vd~~with~positive 
hotropic Effkts 
When administered to patients without heart faihue, most 
vasodikrdrugscankreasecardiaccontmctihtyandheart 
rateiftheirhypotensive&ectsleadtoactivatiouoftbe 
sympathetic nervous system (77). However, because circu- 
la oryretlexmechanismsaremarlcedlyattenuatedinheart 
fbilure (78), most VasodilafMs exert little effect on the heart 
in thii disorder. Yet, some vasodiir drugs (for example, 
hydmla&e and tlosequiuan), when admiuistered in hi@ 
doses, exert direct positive iuotropk and cbrouo&opic ef-
fectsthatarcuot&tedtotheactivationofcardiovascuk 
mtlexes. Thus, these drugs can increase heart rate aud 
cardiacWlltmcUyeVeniapatieutswithheartfaiblre.The 
illlpOHtillCCOfttleSeactionsh~diatingthCClinical~ 
ofthesedrugsisuuhuown. 
w The principal ction of hydralax& inheart 
tuihlreistodi~arteriatmsistancevessels,butiumauy 
patients, the magnitude ofthe hemodynamic huprovement 
pnAtcedbythedrugismodestxudtImsmanyphysicians 
haverecommeadedtheuseofhigherdosesofhydmlaxineiu 
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an attempt tomaximize itshemodynamic benefits (79). The 
hemodynamic advantages of these high doses are in part 
related to their ability to increase cardiac ontractility and 
heart rate (80.81). The biochemical mechanisms that mediate 
the positive inotropic and chronotropic effects of hydrala- 
zinc a~ not understood, but these actions are not reflex in 
nature, although t ey are mediated bythe release of myo- 
cardial catecholamines andthe generation f intracellular 
cAMP in the failii heart (77,82). On the basis of clinical 
experience with beta-agonists and phosphodiesterase inhib- 
itors, these lfects of hydralaxine onCAMP and myocardial 
co~tractihi might be expected to increase the mortality rate 
by 28%. Yet, when combined with isosorbide in&ate in the 
large Vasodilator-Heart F ihue Trial (V-HeFT) (83), hydral- 
azine reduced the mortality of patients with chronic heart 
faihue by 28%. 
What factors can explain this apparent paradox? Some 
physicians have postulated that he benefits ofthe wmbina- 
tion of isosorbide ir&ate and hydralaxine i  the V-HeFT 
were related to the use of nitrates and not to the use of 
hydralazine. However, inthe study, the reduction i mor- 
tality was seen principally in patients who had an increase in 
ejection fraction (sir); such effect is characteristic of hydral- 
axine and not isosorbide dinitmte (85). Furthermore, the 
regression f cellular hypertrophy seen in another study (85) 
with the combination of hydrahuGe and isosorbide initrate 
was primarily related tothe use of hydralaxine rather than to 
the use of the nitrate. Finally, the prolonged use of isosor- 
bide dir&ate in the doses utiliid in the V-HeFT (86) would 
be expected to result in the development of tolerance tothe 
drug. Under such circumstances, hydralaxine would emerge 
as the only effective component of he vaso&tor combina- 
tion. 
At first glance, these findings would suggest that he use 
of a drug with cyclic AMP-dependent positive inotropic 
elf&s could reduce mortality inpatients with heart failure. 
However, it is not clear that he doses of hyd&xine used in 
the V-HeFT study exerted cardiostimuiatwy effects. The 
increaseinheartrnte(2beats/min)seeninthestudywas 
smaller than that seen in other controlled clinical trials (87) 
with hydralax&. The lack of tachycardia may have been 
related to the average dose of hydrahGne administered in 
the V-HeFT study-only 270 &lay-&is dose produces 
only modest hemodynamic e&cts (79), perhaps because it 
exerts effects only on peripheral blood vessels. This obser- 
vation raises the intriguing possibility hat ifhydral&ne had 
been used in higher doses (sutlicient toproduce a positive 
inotropic action). the drug may 0oi have xerted a favorable 
infhtence onsurvival. This hypothesis may explain the poor 
long-term outcome of patients treated with very high doses 
ofhydralazine that were selected toproduce maximal hemo- 
dynamic elf&s (88). 
Elosegpfnan. Flosequinan exerts its hemodynamic e& ts 
in heart failure primarily by dilating arterial resistance and 
venous capacitance v ssels. However, like hydralszine. 
large doses of flosequiuan m exert positive inotropic and 
chronotropic effects that are not retlex in nature but repne- 
sent a direct effect of the drug (81,894). The mecha&ms 
underlying these direct effects are not understood, but they 
may involve an action on sodium-calcium exchange b cause 
the positive inotropic effects of the drug z,re abolished by 
cadmium (92). In contrast tobeta-agonists andphosphodi- 
esterase inhibitors, the &tropic and chronotropic elfects of 
tlosequinan re not mediated by changes in intracellular 
cyclic AMP (92), although t is issue remains controversial 
(93). 
The importance of positive inotropic and chtonotropic 
elfects of flosequinan in mediat@ the clinical beneilts ofthe 
drug in heart faihue is unknown. Low doses of the drug 
(75 q/day) exert virtually no direct effects on the heart, 
whereas hiih doses (150 m&lay) produce consistent in- 
creases in cardiac contractility and heart rate (8994). Inter- 
estingly, these positive inotropic and chronot@c effects 
may enhance the hemodynamic effects of tloscquimm but 
may detract from the drug’s clinical effects. High doses of 
ilosequinan (150 m&lay) are hemodynamically more ff~ 
tive than lower doses (75 to 100 m&lay), but seem to be less 
effective in prolonging exercise tolerance (94%). This par- 
adoxic dose-response relation has been demonstrated when 
ffosequiaan is administered in either the presence or the 
absence of a converting enzyme inhibitor (95.96). The rea- 
sonsforthereducedefRcacyofhighdosesoffktsequinanin 
heart f&hue remain unknown, but his pattern is reminiscent 
of the experience with pimobcnJan d enoximone (69,70). 
In addition, preliminary results of the recently completed 
Piospective Randomixed Flosequinan Longevity Ewduation 
(PROFILE study) indicated that large doses of llosequinan 
were associated with increased mortality, whereas this risk 
was not apparent with the use of lower doses of the drug. 
These observations suggest that he positive tipic and 
chronotropic elfects dRosequinan may limit he eGcacy and 
safety of the drug in the ueatmentofheartfailure. 
C~ClUSiOllS 
These observations, derived ftwm experience witn many 
different pharmacoktgic a ents, indicate that he long-term 
administration of drugs with positive hmtropic e&cts can 
produce important adverse reactions that can limit the 
etllcacy and safety of therapy. Although impressive b mo- 
dynamic mprovement can be observed after the use of 
digit&s, beta- agonists and phospm 
inhibitors, therapy with these drugs frequently fails to pro- 
duce clinical benefits and may increase the mortality of 
treated patients. This risk accompanies the use of all positive 
inotl@cagents,regardlessoftheirmechanismofacti~or 
their effects on heart rate or neurohormonal activity. 
Do these observations i dicate that positive inotropic 
therapy should be abandoned as a thempeutic intervention 
for heart failure? The available data suggest that he &cacy 
andsafetycrfmany(~not~)poaitiveinotropicdnrgscanbe 
greatlyenhancedbyt&cingthedoseofthesedrugs.Low 
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~~sd~ttdthttquinanappeartobe- 
e&ctivetbanlrighdoses,andthetoxicitydbighdosesaf 
~s~begreatlyfminimkdwiththeuseoflowdoses 
ofthesedrugs.Theimportamxofdoseis~~Y 
~-ted by clinical studies of vesnakme, which de- 
creases morr&y when administered in low doses but in- 
~smortali@whenitisadmi&teredin~sdytwke 
as~.‘rhese!Mingssuggestthatdosage~yk:t~ 
&icaldeterminsntdtheeiEcacyandsafetyofpositive 
iWropicdNgsinhear&faihlre. 
~rewg&onoftheimporknceofdoseresolvethe 
contIovcrsy umnmding theuse of positive inotropic drugs? 
Althoqghlowdosesofthesednqsmaybeclinicallysuperiar 
to high doses, itis not clear that such do6es exert signi6cant 
positive inot17# effects. AU positive inotropic drugs exert 
actionsonthecircuMionotherthantheire&ctoncontrac- 
tility, and these noninotropic roperties may be particularly 
important at low do8es of these drugs. For example, low 
doses of hyd&zine, flosequinan, milrinone and pimoben- 
dan may act primarity odilate peripheral blood vessels 
rather than stimulate he heart. Siiy, low doses of 
di#italis may exert only neurohormonal e&&s, and low 
dosesofvesnarinonemayactasanantiarrhythmicagent.If 
these noninot& actions of positive inotropic drugs are 
responsible for their therapeutic bendits, then the actions of 
these drugs to increase cIvdi&c onhWility must be re- 
gtKdUh8llundesirabkeffecttbatphysicians!ihOUklSCCk 
tomiaimize,evenifsuchanactionmayhrrvebeenthe 
primarybasisforthedevelopmentofthedNgforheart 
Mure. In this context, the development of a pure positive 
inotropic wnt-one without any beneficial ncillary 
prop&ies-would not necessarily be qarded as an impor- 
tant herapeutic ouective. 
These obamations w&score the Lgowias realization 
thathemod~cactivityshouldnotbeviewedasapre- 
requisite~thede&pmentofane&ctivedrugforthe 
tmatment ofchronic heart faihu~ (11). Therapeutic in&rven- 
tions may improve the hemodynamic status of patients but 
advemelyatfecttheirlong-termoutcome.Conversely,drugs 
that exert no favorable h nux@&c e&c& may improve 
sWVival.Thee&ctofdrugsonneurohonnonalandel~ 
physiolqjic variables may be more important than their 
e&t oa hemodymunic variables in detemk& the eiIicacy 
and safkty of treatment. Interestingly, despite r cognition f 
theseprinci2des,thedosedanewdrus~heart~~is 
generaUysekctedonthebasisoftheabilityofthedoseto 
paoducefiwmblehemodynamiceffiicts.suchmapproach 
ha8 cawed some di6icuhies in the development ofdiic 
druss~d~~enzymeinhibitors,butthemarginfor 
~~YbepltkUldyslIlaUintheevaluatimofpo8itive 
inotropicdrugs,especiallyifthesedrugsexerttheir4i&d 
benefits~YbYmechanismsthathavelittletodow&h 
~sincardiaclXWlWiEty.Thebeliefthatpositive 
inotropiclycentsfwheartiUlMhoUldbedevekrpedat 
Me for the controversy that has surrounded these drugs for 
the l st ZOO years. 
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